Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2016 | 12-2015 | 12-2014 | 12-2013 | 12-2012 | |
Cash Flows From Operating Activities | |||||
Net Income | -70,171 | -2,301 | -3,278 | 11,768 | -4,261 |
Depreciation Amortization | 56,706 | 29,519 | 19,890 | 17,728 | 17,332 |
Income taxes - deferred | 943 | -2,915 | -2,101 | 125 | 3,368 |
Accounts receivable | -10,787 | -9,353 | -12,664 | -9,987 | -12,207 |
Other Working Capital | 14,966 | -599 | -28,644 | -4,332 | -11,697 |
Other Operating Activity | 34,978 | 25,277 | 28,702 | 12,874 | 22,802 |
Operating Cash Flow | $26,635 | $39,628 | $1,905 | $28,176 | $15,337 |
Cash Flows From Investing Activities | |||||
PPE Investments | -50,740 | -22,010 | -17,109 | -10,835 | -9,443 |
Net Acquisitions | -142,016 | -199,580 | -145,752 | N/A | N/A |
Sale Of Investment | N/A | N/A | N/A | N/A | 213 |
Purchase Sale Intangibles | -441 | -126 | -398 | -411 | -552 |
Other Investing Activity | -441 | -126 | -398 | -411 | -552 |
Investing Cash Flow | $-193,197 | $-221,716 | $-163,259 | $-11,246 | $-9,782 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | 50,344 | N/A | N/A | N/A | N/A |
Debt Issued | 227,792 | 269,661 | 35,000 | 150,000 | 5,000 |
Debt Repayment | -48,961 | -81,864 | -5,063 | -775 | -2,839 |
Common Stock Issued | 2,024 | 3,458 | 2,313 | 24,627 | 531 |
Common Stock Repurchased | -974 | -824 | -579 | -164 | N/A |
Other Financing Activity | -59,380 | -5,015 | 1,570 | -36,803 | -5,226 |
Financing Cash Flow | $170,845 | $185,416 | $33,241 | $136,885 | $-2,534 |
Exchange Rate Effect | -1,626 | -980 | -820 | -1,180 | 288 |
Beginning Cash Position | 49,343 | 46,995 | 175,928 | 23,293 | 19,984 |
End Cash Position | 52,000 | 49,343 | 46,995 | 175,928 | 23,293 |
Net Cash Flow | $2,657 | $2,348 | $-128,933 | $152,635 | $3,309 |
Free Cash Flow | |||||
Operating Cash Flow | 26,635 | 39,628 | 1,905 | 28,176 | 15,337 |
Capital Expenditure | -51,428 | -22,041 | -17,189 | -11,135 | -9,890 |
Free Cash Flow | -24,793 | 17,587 | -15,284 | 17,041 | 5,447 |